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Abstract
Genes involved in invasion of trophoblast cells and angiogenesis are crucial in determining pregnancy outcome. We
therefore studied expression profiles of these genes in both fetal and maternal tissues to enhance our understanding of
feto-maternal dialogue. We investigated the expression of genes involved in trophoblast invasion, namely Kiss1, Kiss1
Receptor (Kiss1R) and MMP9 as well as the expression of angiogenic ligands Vascular Endothelial Growth Factor-A (VEGF-A)
and Prokineticin-1 (PROK1) and their respective receptors (VEGFR1, VEGFR2 and PROK1R) across the feto-maternal interface
of healthy human pregnancies. The placenta, placental bed and decidua parietalis were sampled at elective caesarean
delivery. Real-time RT-PCR was used to investigate transcription, while immunohistochemistry and western blot analyses
were utilized to study protein expression. We found that the expression of Kiss1 (p,0.001), Kiss1R (p,0.05) and MMP9
(p,0.01) were higher in the placenta compared to the placental bed and decidua parietalis. In contrast, the expression of
VEGF-A was highest in the placental bed (p,0.001). While VEGFR1 expression was highest in the placenta (p,0.01), the
expression of VEGFR2 was highest in the placental bed (p,0.001). Lastly, both PROK1 (p,0.001) and its receptor PROK1R
(p,0.001) had highest expression in the placenta. Genes associated with trophoblast invasion were highly expressed in the
placenta which could suggest that the influence on invasion capacity may largely be exercised at the fetal level.
Furthermore, our findings on angiogenic gene expression profiles suggest that angiogenesis may be regulated by two
distinct pathways with the PROK1/PROK1R system specifically mediating angiogenesis in the fetus and VEGFA/VEGFR2
ligand-receptor pair predominantly mediating maternal angiogenesis.
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Introduction
Effective placentation is required for successful pregnancy
outcome. During placentation, transformation of the spiral arteries
from high resistance low capacity vessels to low resistance high
capacity vessels is crucial for successful support of the conceptus
and fetus. The lack of transformation of these spiral arteries is
associated with poor pregnancy outcomes such as preeclampsia
and intrauterine growth restriction (IUGR) [1,2].
The transformation of spiral arteries is determined by adequate
endovascular invasion of extravillous trophoblast (EVT) cells.
Various factors determine the invasion capacity of these cells.
Oxygen tension seems to have different effects on the invasive
phenotypes of trophoblast cells depending on pregnancy duration
[3,4]. The effect of oxygen appears to be mediated via the actions
of Hypoxia Inducible Factor (HIF) and Transforming Growth
Factor b3 (TGFb3) as well as alteration of Matrix Metallopro-
tease-9 (MMP9) expression [5,6]. The ability of EVT cells to
express gelatinases like MMP9 aids extracellular matrix degrada-
tion and enhances invasiveness. The expression of MMP9 in
particular, has been associated with high invasiveness, while that of
Tissue Inhibitors of Metalloproteases (TIMPs) markedly reduces
this invasive potential [7,8].
Kiss1 gene was initially discovered as a tumour metastasis
suppressor gene of melanoma cells in nude mice without affecting
their tumorigenicity [9]. This suppression of metastasis by Kiss1
gene was subsequently demonstrated in various cancer cell-lines as
well as in animal and human cancer experiments [10,11,12]. The
Kiss1 gene encodes peptides known appropriately as kisspeptins
(kp). Posttranslational processing of the original Kiss1 transcript
results in kisspeptins of various lengths (kp-145, kp-54 also known
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as metastin, kp-14, kp-13 and the smallest cleavage product kp-10).
Kisspeptins are natural ligands of G-Protein Coupled Receptor 54
(GPR54) also known as Kiss1 Receptor (Kiss-1R) [13,14,15].
The molecular machinery and pathways involved in tumour
metastasis and invasion of extravillous trophoblast (EVT) cells into
the maternal decidua are similar [16]. However the invasiveness of
trophoblast cells is highly regulated temporally and spatially. The
highest invasion is observed in the first trimester of pregnancy and
geographically only extends as deep as the inner third of the
myometrium. The clinical repercussions of ‘‘overinvasion’’ and
‘‘underinvasion’’ are placenta accreta as well as preeclampsia and
IUGR, respectively. The former leads to massive obstetric
haemorrhage secondary to retained placenta at the time of
delivery while the latter (a consequence of maternal vascular
maladaptation), contributes significantly to maternal and perinatal
mortality, particularly in the developing world [17]. Kisspeptins
limit the invasion of primary trophoblast cells and EVT cell-lines
in vitro [18]. Furthermore up-regulation of Kiss1 expression and
down-regulation of MMP9 gene expression have been associated
with pregnancies complicated by preeclampsia and IUGR [19,20].
Interplay between diverse factors affecting EVT invasion
comprises a delicate equilibrium between pro-invasive and anti-
invasive factors which is required for adequate invasion and a
healthy gestation. Genes involved in angiogenic pathways appear
to play a central role in achieving this equilibrium because
ultimately the final common pathway to trophoblast invasion is
spiral arteriolar transformation. In addition it has been demon-
strated that the transformation of EVT cells from expressing an
epithelial-type cell adhesion profile to an endothelial-type one
enhances their invasiveness and subsequent transformation of
spiral arteries [21].
The majority of factors involved in trophoblast invasion have
mainly been studied in the fetal compartment of the feto-maternal
interphase i.e. the placenta. Very few studies have examined both
Table 1. Primers and Probe Sequences used for Real-Time (RT) PCR Reactions.
1GPR54 Forward Primer 5’-GGTGCTGGGCGACTTCAT-3’
GPR54 Reverse Primer 5’-CACACTCATGGCGGTCAGAGT-3’
GPR54 Probe 5’-[FAM]-TGCAAGTTCGTCAACTACATCCAGCAGG-[TAMRA]-3’
2Kiss1 Forward Primer 5’-GGCAAGCCTCAAGGCACTT-3’
Kiss1 Reverse Primer 5’-GGAAAAGCAGTAGCTGCCAAGA-3’
Kiss1 Probe 5’-[FAM]-TGCCTCTTCTCACCAAGATGAACTCACTGG-[TAMRA]-3’
3PROK1 Forward Primer 5’-GTG CCA CCC CGG CAG-3’
PROK1 Reverse Primer 5’-AGC AAG GAC AGG TGT GGT GC-3’
PROK1 Probe 5’-[FAM]-ACA AGG TCC CCT TCT TCA GGA AAC GCA-[TAMRA]-3’
4PROKR1 Forward Primer 5’-TCT TAC AAT GGC GGT AAG TCC A-3’
PROKR1 Reverse Primer 5’-CTC TTC GGT GGC AGG CAT-3’
PROKR1 Probe 5’-[FAM]-TGC AGA CCT GGA CCT CAA GAC AAT TGG-[TAMRA]-3’
5VEGF Forward Primer 5’-TAC CTC CAC CAT GCC AAG TG-3’
VEGF Reverse Primer 5’-TAG CTG CGC TGA TAG ACA TCC A-3’
VEGF Probe 5’-[FAM]-ACT TCG TGA TGA TTC TGC CCT CCTCCT T-[TAMRA]-3’
6MMP9 Forward Primer 5’-GGCCACTACTGTGCCTTTGAG-3’
MMP9 Reverse Primer 5’-GATGGCGTCGAAGATGTTCAC-3’
MMP9 Probe 5’-[FAM]-TTGCAGGCATCGTCCACCGG-[TAMRA]-3’
7VEGFR2 Forward Primer 5’-TTA CAG CTT CCA AGT GGC TAA GG-3’
VEGFR2 Reverse Primer 5’-ATT TTA ACC ACG TTC TTC TCC GAT AA-3’
VEGFR2 Probe 5’-[FAM]-CTT GGC ATC GCG AAA GTG TAT CCA CA-[TAMRA]-3’
8VEGFR1 Forward Primer 5’-ATG TGC CAA ATG GGT TTC ATG T-3’
VEGFR1 Reverse Primer 5’-ACT TGT TAA CTG TGC AAG ACA GTT TCA-3’
VEGFR1 Probe 5’-[FAM]-CTC TCC TTC CGT CGG CAT TTT TTC CAA-[TAMRA]-3’
1G-Protein Coupled Receptor 54 (Kiss1 Receptor)
2Metastasis Suppressor Gene (Kiss1)
3Prokineticin1
4Prokineticin1- Receptor
5Vascular Endothelial Growth Factor
6Matrixmetalloprotease-9
7Vascular Endothelial Growth Factor Receptor 2
8Vascular Endothelial Growth Factor Receptor 1
doi:10.1371/journal.pone.0063574.t001
Table 2. Clinical Data.
Age (years) Gravidity Parity Gestation (weeks)
28.4760.87 2.43360.18 1.160.16 38.0360.06
Table 2 depicts patients clinical data presented as means with standard error of
the means (means 6SEM) showing Age (in years), Parity (number of
pregnancies that have reached viability), Gravidity (number of pregnancies
irrespective of viability) and Gestation (duration of pregnancy in weeks).
doi:10.1371/journal.pone.0063574.t002
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sides of this interface concomitantly. To better understand the
molecular and cellular interactions involved in feto-maternal
dialogue, both components of this interface should be studied in
healthy pregnancies before even exploring pathological pregnan-
cies.
In this study, we examined the gene expression profiles of Kiss1
and its cognate receptor GPR54 (Kiss1R) in the placenta, placental
bed and decidua parietalis. In addition we investigated the
expression profiles of gelatinase B (MMP9) which is involved in
extracellular matrix degradation across the three feto-maternal
tissue compartments. Lastly, the expression of genes involved in
angiogenesis, namely Vascular Endothelial Growth Factor A
(VEGF-A), Prokineticin-1 (PROK1) also known as Endocrine
Gland-specific VEGF (EG-VEGF) and their respective receptors
(VEGFR1, VEGFR2) and PROK1R were investigated in the
placenta, placental bed and decidua parietalis.
Materials and Methods
Ethics Statement
The study was approved by the Human Research Ethics
Committee of the Faculty of Health Sciences, University of Cape
Town (REF: 080/2008). Written informed consent was obtained
from all patients and the research was conducted according to the
ethical principles of the Helsinki Declaration [22]. Patients were
counselled prior to the day of their elective procedure in their
preferred language of choice. They were presented with Patient
Information Leaflets (PILs) which provided the details of the study.
The capacity of the patients to comprehend this information was
always assessed and where there was doubt about comprehension,
consent for study participation was not taken. Within the consent
form, there was a section reassuring the patients that their decision
involving participation in the study would not in any way
Figure 1. Kiss1 and GPR54 (Kiss1 R) expression in the Placenta, Placental bed and Decidua parietalis. Real-time PCR (Means 6 SEM)
showing Kiss1 (Fig. 1a) and GPR54 (Fig. 1b) expression in the three feto-maternal compartments. (***) and (*) signify p,0.001 and P,0.05
respectively. Fig. 1c shows kisspeptin immunostaining in the Placenta, Placental Bed and Decidua Parietalis, with kisspeptin protein expression (green
fluorescent staining) in the placental syncitiotrophoblast (sTB) layer. Smooth Muscle Actin (yellow) was used as a positive control for slide staining
and can be seen staining vascular smooth muscle (vsm) and smooth muscle (sm). The decidua basalis (db) and decidua parietalis (dp) can be seen in
the placental bed and decidual sections respectively. Kisspeptin staining is negative in the placental bed and decidua parietalis. The nuclei were
stained with Dapi (blue).
doi:10.1371/journal.pone.0063574.g001
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compromise their further management and care. The patients
were at liberty to make this choice without any force or coercion.
Study Participants
All patients recruited had elective caesarean section deliveries in
the absence of labour. The inclusion criteria for the study were
healthy patients undergoing elective caesarean section for the
indication of previous caesarean section or fetal malpresentation.
Patients in labour, with a background of two previous caesarean
sections, with pregnancy-related complications such as gestational
diabetes, gestational hypertention, placenta praevia, preeclampsia,
intrauterine growth restriction as well as patients with underlying
medical disorders were excluded from the study. Patients were
recruited from Groote Schuur and Mowbray Maternity Hospitals
in Cape Town, South Africa.
Tissue Sampling and Specimen Collection
The placenta and placental bed were sampled at elective
caesarean section using a previously described technique [23].
Briefly, prior to delivery of the placenta, apposing sections of the
placenta and placental bed were marked by placing a needle and
suture from the placenta and traversing the uterine wall. A core of
the placental tissue around the suture in apposition to the maternal
surface (i.e which contains the maternal end of the placenta) was
then sampled and the rest of the placenta delivered. The section of
the placental bed where the sampled placenta was resident could
then be identified with the aid of the remaining suture and was
subsequently biopsied. The adequacy of the sampled placental bed
was confirmed by an independent histopathologist (L.M). In
addition, the decidua parietalis which has no involvement with
placentation was sampled. Collected tissue samples were divided
into three portions. One portion was collected for RNA extraction,
while the second and third portions were utilised for protein
extraction and preparation of wax-embedded tissue blocks
respectively.
RNA Extraction
1 ml of TRIzolH reagent (InvitrogenTM) was used per 50 mg of
tissue. Tissue was homogenised on ice with a Tissue RuptorH
(Qiagen). The homogenate was centrifuged using the Eppindorff
5804 R machine (15294 g at 4uC for 15 minutes (mins)) and the
supernatant was collected and added to 200 ml of ice-cold BCP (1-
Bromo-3-Chloro-Propane (Sigma). The mixture was shaken for 15
seconds (secs) and kept on ice for 10 mins. The solution was
centrifuged again and 500 ml of propanol was added to precipitate
the RNA. The RNA pellets were washed in 75% ethanol, air dried
and re-suspended in DEPC- treated water.
cDNA Synthesis
RNA was reverse transcribed with Multiscribe Reverse Tran-
scription reagents (Applied Biosystems). For a 20 ml reverse
transcription reaction, the following were used; DEPC-treated
H2O (3.7 ml), 10x RT Buffer (2 ml), MgCl2 (4.4 ml), dNTPs (4 ml),
Random Hexamers(1 ml), RNAse Inhibitor (0.4 ml), Reverse
Transcriptase (0.5 ml) and (2 ml) of RNA. The ABI GeneAmpH
2700 Thermal Cycler was used and the cycling parameters were
25uC (10 mins), 4uC (10 mins), 48uC (45 mins) and 95uC (5 mins).
Real-Time PCR
Gene expression studies were conducted using the ABI
7900 RT-PCR instrument (Applied Biosystems). The standard
thermal cycling protocol was conducted as follows: 50uC for
2 mins, 95uC for 10 mins and 40 cycles of (95uC for 95 secs and
60uC for 1 min). The Genebank accession numbers of the genes
investigated are as follows: KiSS1 (NM_002256), KiSS1R
(NM_032551), MMP9 (NM_004994), VEGFA (NM_001171623),
VEGFR1 (FLT) (NM_002019), VEGFR2 (KDR) (NM_002253),
PROK1 (NM_032414), PROKR1 (NM_138964). Primer/Probe
pairs corresponding to these genes (SigmaH Pharmaceuticals) were
utilised (Table 1) in conjunction with the TaqmanHMastermix. All
RT-PCR gene expression data is presented as Means 6 SEM and
gene expression was relative to 18 s ribosomal RNA (internal
control) and reference cDNA.
Immunohistochemistry
Tissue blocks were sectioned and fixed to slides (HistobondH)
with the placenta, placental bed and decidua parietalis fixed across
one slide and stained together.
Kisspeptin immunostaining. Slides were de-waxed in
xylene and rehydrated in decreasing concentrations of ethanol.
Antigen retrieval was done by pressure cooking the slides in
0.01 M Citrate Buffer. The slides were then blocked in 10%
Methanol Hydrogen Peroxide for 30 mins, washed in water and
then TBS (Tris-Buffered Saline). Normal Donkey Serum (NDS)
Figure 2. GPR54 (Kiss1R) immunostaining in the Placenta. Fig. 2 (a–c) demonstrate GPR54 immunohistochemistry with individual villous
cytotrophoblast cell staining for GPR 54 (red) in the placental villus (pv) (Fig. 2a). Fig. 2b shows GPR54 (red) immunostaining of villous
cytotrophoblasts (vCT), cytotrophoblast columns (CC) and extravillous trophoblast cells (EVTs). The placenta is stained with GPR54 pre-immune serum
(negative control) in Fig. 2c. The nuclei are stained with Sytox Green (green).
doi:10.1371/journal.pone.0063574.g002
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was used for blocking followed by incubation with Sheep anti-
kisspeptin54 (GQ2) antibody (1:1500) (provided by Professor
Bloom’s laboratory) overnight at 4uC. Thereafter slides were
washed in TBS (265 mins) and incubated for 30 mins with
secondary Donkey anti-Sheep Peroxidase antibody (Jackson
Immunoresearch) (1:750) (1.8 mg/ml).
The slides were washed again in TBS (365 mins) and incubated
for 10 mins with Tyramide Cyanine-5 (Perkin Elmer) (1:50).
Thereafter slides were washed in TBS (265 mins) and micro-
waved in citrate buffer for 2.5 mins and incubated in hot buffer for
30 mins. They were then washed in TBS and incubated with
Mouse anti-a-Smooth Muscle Actin antibody (Sigma Aldrich)
(1:5000) for 1 hour. After washing in TBS, secondary Donkey
anti-Mouse-555 (DAM-555) (1:200) (2 mg/ml) (Invitrogen) anti-
body was applied for 30 mins and washed off with TBS. Nuclear
stain DAPI 405, (1:1000 in PBS), was applied for 10 mins at room
temperature and washed in TBS. Slides were then mounted with
PermaflourH and viewed with Zeiss LSM 710 META confocal
microscope.
GPR54 immunostaining. The same protocol as above was
followed except no antigen retrieval was required and Normal
Goat Serum was used for blocking. Primary Rabbit anti-GPR54
(R2 1213) custom manufactured by EZ Biolabs (1:1600) was used.
Pre-immune serum was utilised as negative control. Goat anti-
Rabbit Peroxidase (1:200) (Dako) was used as secondary antibody
followed by Tyramide-546 (Cyanine-3) (Perkin Elmer). Sytox
Green (1:1000 in TBS) was used to stain the nuclei.
MMP9 immunostaining. The slides were de-waxed and
rehydrated. Heat-mediated antigen retrieval in 0.01 M citrate
buffer was followed by quenching endogenous peroxide with 30%
Figure 3. MMP9 expression in the Placenta, Placental Bed and Decidua Parietalis. Fig. 3a shows relative MMP9 mRNA expression based on
RT-PCR in the Placenta, Placental Bed and Decidua Parietalis. (***) and (**) signify p,0.001 and p,0.01 respectively. Fig. 3b depicts localization of
MMP-9 protein at the three feto-maternal sites. In the placenta MMP9 immunostaining (red) was observed in the villous mesenchyme (vM) as well as
the villous trophoblast cells (vT) of the placental villus (pv). In the placental bed MMP9 staining was mainly located on the decidual border of the
decidua basalis (Db). In comparison, there was minimal MMP9 staining in the border of the decidua parietalis (Dp).
doi:10.1371/journal.pone.0063574.g003
Feto-Maternal Gene and Protein Expression
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Figure 4. The expression of VEGF-A in the Placenta, Placental Bed and Decidua Parietalis. Real-time PCR (Means 6 SEM) showing mRNA
expression of VEGF-A (Fig. 4a), in the three feto-maternal compartments. (***) and (**) signify p,0.001 and p,0.01 respectively. The highest VEGF-A
mRNA is expressed in the placental bed. Fig. 4b shows VEGF-A Western Blot Analysis of the Placenta, Placental Bed and Decidua Parietalis obtained
from different patients. Bands are present in both the maternal Placental Bed (PB) and Decidua Parietalis (DP). Bands between 20 and 40 Kd represent
the various VEGF-A isoforms. The molecular weight of the VEGF is 20 Kd (Kilodaltons) while that of the homodimer is 40 Kd. Figure 4c demonstrates
VEGF-A immunostaining in the placenta with VEGF-A protein expression (red) in both the syncytiotrophoblast (sTB) and cytotrophoblast (cTB) cell
layers of the placental villus (pv). VEGF-A staining is also observed in the endothelial cells of villous capillary vessels (vCv). DAPI (blue) is used to stain
the nuclei. Fig. 4d shows co-localisation of VEGF-A (red) and Pancytokeratin (PCK) (green) in a cluster of Extravillous Trophoblast (EVT) cells staining
yellowish-orange. Multinucleated Trophoblast Giant Cells (TGCs) can be seen amongst the EVTs. The lumen of a spiral artery (SA) containing red
blood cells can be noticed on the left. DAPI (blue) was used to stain nuclei. The nuclei of the TGCs are different in morphology and size in comparison
to those of the surrounding cells.
doi:10.1371/journal.pone.0063574.g004
Feto-Maternal Gene and Protein Expression
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methanol hydrogen peroxide. Blocking to prevent non-specific
antibody binding was done with NDS and primary rabbit anti-
MMP9 antibody (ab38898 (1 mg/ml)) (1:200) from AbcamH was
applied overnight. Donkey Anti-Rabbit-555 (1:1000) (A31572
from Invitrogen) was used as secondary antibody followed by
DAPI staining for nuclei.
PROK1 immunostaining. The slides were prepared as
above with antigen retrieval, blocked with NDS and incubated
with primary Rabbit anti-PROK1 antibody (AbcamH) (1:50) in
NDS. Donkey Anti-Rabbit-555 (DAR-555) (1:1000) (2 mg/ml)
from Invitrogen was used as secondary antibody and the nuclei
were stained with DAPI (1:1000 in PBS).
VEGF-A immunostaining. Slides were de-waxed, rehydrat-
ed, antigen retrieved and bathed in hydrogen peroxide for
30 mins. Blocking was done with NDS. Rabbit Anti-VEGF A
antibody (VEGF (sc-152) (1:50) (200 mg/ml) (Santa Cruz) and
DAR-555 (1:1000) were used as primary and secondary antibody
respectively. The nuclei were stained with DAPI.
VEGF-A and pancytokeratin Co-Immunostaining. Slides
were de-waxed, rehydrated, antigen retrieved and blocked with
methanol hydrogen peroxide. NDS was used for blocking. Rabbit
Figure 5. The Expression of VEGF Receptors in the three feto-maternal compartments. Fig. 5a demonstrates VEGFR1 and Fig. 5b shows
VEGFR2 mRNA expression in the placenta, placental bed and decidua parietalis. The placenta has highest VEGFR1 mRNA expression (Fig. 5a) while the
placental bed has highest expression of VEGFR2 mRNA (Fig. 5b). Figure 5c demonstrates VEGFR1 and VEGFR2 co-immunostaining in the placenta and
placental bed and decidua parietalis. In the placental section VEGFR1 (green) staining can be seen in the cytotrophoblast columns (CC) and
extravillous trophoblast (EVT). No VEGFR2 staining (red) was observed in the placental sections. Red blood cells (RBCs) auto-flouresce with both green
and red dyes and can be seen (yellow) in the image. In the placental bed section both VEGFR1 (green) and VEGFR2 (red) staining were detected.
VEGFR1 staining was observed in the interstitial extravillous trophoblast (EVT) of the decidua basalis while VEGFR2 staining was limited to the
decidual stroma. There was comparatively minimal VEGFR1 and VEGFR2 staining in the decidua parietalis (Dp).
doi:10.1371/journal.pone.0063574.g005
Feto-Maternal Gene and Protein Expression
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anti-VEGF-A (1:50) and Mouse anti-Pancytokeratin (1:15000)
(Sigma) were applied to the slides and incubated overnight. DAR-
555 (1:1000) and Goat Anti-Mouse Alexa-488 (1:500) in NDS
were used as secondary antibodies. DAPI was used to stain the
nuclei.
VEGFR1 and VEGFR2 Co-Immunostaining. The slides
were de-waxed and rehydrated. Heat-mediated antigen retrieval
was done in 0.01 M Citrate buffer followed by quenching of
endogenous tissue peroxidase activity with 30% methanol
hydrogen peroxide for 30 minutes. NDS was employed to block
non-specific antibody binding. The slides were incubated simul-
taneously with mouse anti-VEGFR1 (ab9540) and rabbit anti-
VEGFR2 antibody (ab2349) from AbcamH. Goat Anti-Mouse
Alexa-488 and Donkey Anti-Rabbit-555 were used concurrently
as secondary antibodies. DAPI was utilised for nuclei staining.
Protein Extraction and Quantification
RIPA lysis buffer (25 mM Tris HCl pH 7.6, 150 mM NaCl, 1%
Triton X, 1% sodium deoxycholate and 0.1% SDS) was used for
tissue lysis. 4 M Urea and protease inhibitor tablets (RocheH) were
added to the buffer. The tissue was incubated on ice for 30 mins,
then poured into a mortar, snap-frozen with liquid nitrogen and
crushed into fine powder using a pestle. The powder was collected
in 2 ml epindorff tubes and centrifuged at 12000 rpm for 15 mins
@ 4uC. The supernatant was collected and protein concentration
quantified using the Pierce BCA Protein Assay Kit (Thermo-
scientific).
Western Blot Analysis
20 mg of protein/well was loaded after denaturing in loading
buffer at 95uC for 5 mins. The proteins were separated on a 15%
SDS-PAGE gel run at 110 V for 80 mins. The gel was then
blotted onto a 0.45 mm PVDF membrane (Amersham Hybond-P)
using NovexH Semi-dry Blotter (Invitrogen). The membranes were
blocked at room temperature for 1hour in 3% BSA and then
incubated at 4uC overnight with Rabbit anti-VEGF-A antibody
(sc-152) (1:50). For negative control the membrane was pre-
incubated with a mixture of anti-VEGF-A and VEGF-A blocking
peptide (AbcamH). After washing, Goat anti-Rabbit Peroxidase
(1:5000) was applied and the blot was visualised using a film
(Amersham HyperfilmTM ECL- GE Healthcare Limited). Beta-
Actin (b-Actin) was used as loading control.
Statistical Analysis
Graphpad 5 Prism software (version 5.00 for Windows,
GraphPad Software, San Diego California USA, www.graphpad.
com) was utilised for statistical analysis with One-Way ANOVA
followed by Dunn’s Multiple Comparison’s Test. P,0.05
conferred statistical significance.
Results
Clinical Data
Twenty-eight patients with healthy pregnancies were included
in the study. The indications for caesarean section were a previous
caesarean section in 23 patients (82.14%) and malpresentations in
five (17.86%) patients. The clinical parameters are presented as
means with standard error of the means (Mean 6 SEM) (Table 2).
Kiss1 and GPR54 Expression are Highest in the Placenta
The expression of Kiss1 and GPR54 genes in the placenta,
placental bed and decidua was determined by RT-PCR (Fig. 1).
There was seven times more Kiss1 expression in the placenta
compared to the placental bed and eighteen times more Kiss1
expression in the placenta compared to the decidua parietalis
(p,0.001). However there was no significant difference in Kiss1
gene expression between the placental bed and the decidua
parietalis. The gene expression level of Kiss1R was modestly higher
(1.6 times) in the placenta compared the placental bed and
decidua parietalis (Fig. 1b) and its expression in the placenta was
much lower compared to that of Kiss1.
Immunohistochemical studies detected kisspeptin protein ex-
pression only in the placenta (Fig. 1c). Kiss1R (GPR54) protein
was expressed in the placenta and localized to the villous
syncitiotrophoblast and cytotrophoblast cell layers as well as the
extravillous trophoblast cell population (Fig. 2a–c). No GPR54
immunostaining was observed in the placental bed and decidua
basalis (data not shown).
MMP9 Transcript Expression is Highest in the Placenta
Next we determined the MMP9 mRNA expression in the three
feto-maternal tissues. We found that MMP9 mRNA expression
was at least two-fold higher in the placenta compared to the
placental bed and four-fold higher in the placenta compared to the
decidua parietalis (Fig. 3a). Immunohistochemistry was used to
localize MMP9 protein in the placenta, placental bed and decidua
parietalis (Fig. 3b). MMP9 protein was localized in the villous
trophoblast cells and mesenchyme of the placenta while in the
placental bed the epithelial border of the decidua basalis stained
positive for MMP9. There was minimal MMP9 staining in the
decidua parietalis.
VEGF-A Gene and Protein Expression are Highest in the
Placental Bed
VEGF-A gene expression was 7-fold higher in the placental bed
compared to the placenta (p, 0.001) and 1.6-fold higher in the
placental bed compared to the decidua parietalis (Fig. 4a). Western
Blot analysis confirmed RT-PCR findings showing more VEGF-A
protein expression in the placental bed and decidua parietalis
compared to the placenta (Fig. 4b). Immunostaining of placental
sections showed mild VEGF-A staining of the syncytiotrophoblast,
cytotrophoblast as well as staining of villous capillary endothelial
cells (Fig. 4c). On the other hand, we observed strong VEGF-A
immunostaining in the placental bed sections relative to the
placenta and decidua parietalis (not shown). Immuno-colocaliza-
tion of VEGF-A and Pancytokeratin (a marker for trophoblast
cells) revealed that placental bed VEGF-A expression was
predominantly from extravillous trophoblast cells and trophoblast
giant cells (Fig. 4d).
VEGFR1 and VEGFR2 Transcripts and Protein are
Differentially Expressed Across the Feto-maternal
Interface
VEGF-A mediates its effects via interaction with a number of its
receptors. We examined the mRNA expression of receptors VEGF
Receptor 1 (VEGFR1) and VEGF Receptor 2 (VEGFR2) in the
feto-maternal tissues. VEGFR1 also known as FLT (fms-like
tyrosine kinase) expression was highest in the placenta (3-fold
higher expression in the placenta compared to the placental bed
and 7-fold higher expression in the placenta compared to the
decidua parietalis) (Fig. 5a). In contrast, VEGFR2 also called KDR
(Kinase Domain Receptor) mRNA expression was highest in the
placental bed (almost 4-fold more expression compared to the
placenta) (Fig. 5b). Using immunohistochemical co-localisation of
VEGFR1 and VEGFR2, we found that VEGFR1 was expressed by
the cytotrophoblast columns (CC) as well as extravillous cytotro-
phoblast (EVT) in the placental sections and interstitial trophoblast
Feto-Maternal Gene and Protein Expression
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cells in the placental bed. There was minimal staining of VEGFR2
in the placenta but the most staining for this receptor was
demonstrated in the placental bed. VEGFR2 staining in the
placental bed was neither from interstitial trophoblast nor decidual
macrophages as verified with CD68 staining (data not shown) but
was limited to the decidual stroma.
PROK1 and PROK1R Transcript and Protein Expression are
Highest in the Placenta
The gene expression of both Prokineticin 1 (PROK1) (otherwise
known as Endocrine Gland specific VEGF (EG-VEGF)) and its
receptor PROK1R were highest in the placenta compared to the
placental bed and decidua parietalis (Fig. 6a and 6b). Minimal
PROK1 immunostaining was observed in the extravillous
trophoblast cells (EVTs) of placental bed sections (Fig. 6c). In
Figure 6. PROK1 and PROK1R expression in the Placenta, Placental Bed and Decidua Parietalis. Real-time PCR (Means 6 SEM) showing
PROK1 (Fig. 6a) and PROK1R (Fig. 6b) mRNA expression in the three feto-maternal compartments. (***), (**) and (*) signify p,0.001, p,0.01 and
p,0.05 respectively. Fig. 6c and 6d show comparative PROK1 and VEGF-A staining in the placental bed respectively. There is minimal PROK1 staining
(red) in the placental bed (Fig. 6c). In comparison Fig. 6d demonstrates strong VEGF-A immunostaining (red) of extravillous trophoblast cells (EVTs) in
the placental bed. Dapi (blue) was used to stain the nuclei.
doi:10.1371/journal.pone.0063574.g006
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contrast VEGF-A immunostaining was strong in the interstitial
EVTs of the placental bed (Fig. 6d). Immunostaining of the
placental sections localized PROK1 protein to the microvillous
border of the placental syncytiotrophoblast layer (Fig. 7).
Discussion
Understanding normal feto-maternal dialogue is the first step in
deciphering pregnancy-related complications and can be valuable
in optimizing assisted reproductive technology. In this paper we
investigated the expression profiles of genes involved in tropho-
blast invasion and angiogenesis which are both essential for
placentation. We examined the expression of Kiss1, VEGF-A,
PROK1 and their respective receptors GPR54, VEGFR1, VEGFR2
and PROK1R as well as the expression of MMP9 in the placenta,
placental bed and decidua parietalis. The study was conducted in
a population of young healthy patients mostly in their second
pregnancies with no pregnancy-related complications or chronic
medical illnesses.
Kisspeptin via its receptor, GPR54 has previously been shown
to play an important role in tumour metastasis suppression and
trophoblast invasion. To our knowledge, Kiss1, kisspeptin and
GPR54 have never been investigated across feto-maternal tissues in
particular the maternal placental bed and decidua parietalis. We
observed strikingly high Kiss1 gene expression in the placenta and
virtually no kisspeptin (protein) expression in the maternal tissues
(placental bed and decidua parietalis). In contrast, GPR54 gene
expression in the maternal tissues was only 50% less than that
expressed in the placenta. Kisspeptin and GPR54 have previously
been shown to inhibit trophoblast invasion in an autocrine/
paracrine manner in primary human trophoblasts [18]. The
maternal expression of GPR54 may therefore play a role in
limiting excessive invasion of trophoblast cells in the maternal
tissues while the high placental kisspeptin and GPR54 expression
may be involved in fetal autoregulation of maternal tissues (Fig. 8).
This may suggest that the control of trophoblast invasion via the
kisspeptin/GPR54 pathway is primarily exercised at the fetal level
and is not only restricted to the first trimester but maintained to
term. Kisspeptin could therefore have a role in the maintenance of
placental invasive homeostasis until term.
We further demonstrated high MMP9 expression in the
placenta which likely enhances the ability of the fetus to invade
the maternal tissues via degradation of extracellular matrix.
Kisspeptin downregulates MMP9 expression in various cancers
[24,25] and this may be the mechanism by which kisspeptin
inhibits trophoblast invasion. Furthermore, Kiss1 has been shown
to reduce MMP9 transcription by interfering with NFkb binding
to the MMP9 promoter in a cell line model [25]. Downregulation
of MMP9 expression is associated with poor fetal growth and
maternal preeclampsia [20,26,27] most likely by a mechanism
involving limited trophoblast invasion and poor transformation of
maternal spiral arteries. These data demonstrate the importance of
the expression of gelatinases (amongst other proteases) by the fetal
compartment in sustaining healthy pregnancies.
In our study VEGF-A expression was highest in the maternal
compartment (placental bed), yet the focus in the literature is
largely on VEGF expression in the placentae of pathological
pregnancies [28,29,30,31,32,33]. Consistent with our RT-PCR
findings, we found VEGF-A protein expression to be highest in the
placental bed and decidua parietalis. We have further demon-
strated that the extravillous trophoblast (EVTs) and Trophoblast
Giant Cells (TGCs) express VEGF-A protein in the placental bed.
A study using in-situ hybridization showed that macrophages in
the maternal decidua [34] expressed the highest VEGF-A mRNA
however our studies detecting VEGF-A protein clearly showed
localization to EVTs and minimal VEGF-A localization to
Figure 7. PROK 1 immunostaining in placental tissue. PROK1 immunostaining (red) can be seen most abundantly towards the microvillous
brush border (BB) of the syncytiotrophoblast layer in Fig. 7a. The nuclei were stained with DAPI (blue). Morphological detail of the villous
cytotrophoblast (cTB) and syncytiotrophoblast (sTB) cells are indicated (top right). The PROK1 primary antibody was omitted in Fig. 7b (negative
control) and no PROK1 immunostaining is demonstrable (top left and bottom right).
doi:10.1371/journal.pone.0063574.g007
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macrophages. Future studies investigating pregnancy pathologies
should therefore focus on VEGF-A expression changes in the
placental bed rather than in the placenta.
When examining VEGF receptors, we found the expression of
VEGFR1 to be highest in the placenta while that of VEGFR2 was
highest in the maternal placental bed and decidua. VEGFR1 also
known as the ‘‘decoy’’ receptor, is thought to bind to VEGF-A and
thus scavenge and reduce the amount of bioavailable VEGF-A to
bind to VEGFR-2 (which mediates its angiogenic and mitogenic
effects) [35,36]. We found low VEGF-A and high VEGFR1 in the
placenta. VEGF-A may (via interaction with VEGFR1) be
suppressed in the placenta while VEGFR2 mediates the angio-
genic and mitogenic effects of VEGF-A in the maternal placental
bed. Interestingly immunohistochemical stainining for VEGFR1
Figure 8. Schematic representation of the feto-maternal interface. Fig. 8a represents a longitudinal section of the anatomy of the feto-
maternal interface while the putative molecular interactions at this interface are depicted in Fig. 8b.
doi:10.1371/journal.pone.0063574.g008
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was strong in extravillous trophoblast (cytotrophoblast columns in
the placenta and interstitial trophoblast in the placental bed).
Could this possibly be a mechanism by which these invading
‘‘fetal’’ cells suppress maternal angiogenesis in favour of their own
angiogenic enhancement? Previously high expression of VEGFR1
both in the placenta and circulation (sFLT1) of pregnant women
has been reported and was thought to regulate the action of
VEGF-A in successful pregnancies [37]. On the other hand, both
VEGF-A and VEGFR2 protein expression are reduced in the
placentae of first trimester miscarriages compared to healthy
controls [38]. Furthermore both VEGF as well as VEGF receptor
knockout mice result in embryonic lethality [39,40,41]. This
indicates the importance of VEGF-mediated vasculogenesis and
angiogenesis in early pregnancy. Our findings suggest that VEGF-
A may be more important in the placental bed than the placenta
in healthy human pregnancies at term. This would imply the
potential role of a different angiogenic factor other than VEGF in
maintaining placental angiogenesis after de novo vasculogenesis is
mediated by VEGF in early pregnancy.
Our study has demonstrated using RT-PCR that both the
mRNA expression of PROK1 and PROK1R were highest in the
placenta while that of VEGF-A was highest in the placental bed.
PROK1 and its cognate receptor PROK1R have recently been
shown to be important tissue-specific role players in the
angiogenesis of steroidogenic organs like the ovary, testis, adrenal
and the placenta [42]. The action of PROK1 is thought to be
complementary to that of VEGF in these tissues. PROK1 has also
been shown to be important in enhancing feto-maternal dialogue
in receptive endometrium [43] and thus likely to be important in
early healthy pregnancies.
By employing immunohistochemical analysis on first trimester
placental tissue another study demonstrated the differential
expression of VEGF and PROK1 in the placenta, with the
former being expressed in the cytotrophoblast and EVT cells
whilst the latter was distinctly expressed in the syncytiotrophoblast
[44]. Of importance, this study found no PROK1 staining in the
extravillous trophoblast. The same group also demonstrated
differential placental expression of these genes with gestation,
with PROK1 and PROK1R, increasing between 8 and 10 weeks of
gestation while that of VEGF remained unaltered throughout the
first trimester. They concluded that their data suggested comple-
mentary roles of PROK1 and VEGF in early pregnancy.
Taken together, these data is suggestive of distinct but
complementary roles of these angiogenic factors where VEGF-A
and its mitogenic receptor VEGFR2 may be mainly, but not
exclusively, be responsible for mediating maternal angiogenesis
and spiral arteriolar transformation in the placental bed while
PROK1 and PROK1R exclusively mediate placental villous
angiogenesis in the fetus. VEGF-A likely plays a critical role in the
initial stages of villous capillary vasculogenesis and early angio-
genesis (as evidenced by lethality in VEGF receptor and ligand
knockout embryos) and may facilitate integration of invasive EVT
cells into the maternal vascular system. PROK1 on the other hand
is potentially involved in maintaining angiogenesis after VEGF-A
has initiated vascular events in early pregnancy.
Kisspeptin could in addition to inhibition of metalloprotease
activity, accomplish its anti-metastasic effects through the
suppression of angiogenesis via factors such as VEGF and
PROK1. Kisspeptin has been shown to reduce HUVEC (Human
Umbilical Vein Endothelial Cells) migration, invasion and tube
formation via Specificity Protein-1 (SP1) mediated suppression of
VEGF expression [45]. Kisspeptin was subsequently shown to
inhibit both new vessel sprouting and tube structure formation in
HUVECs in a dose dependant manner [46]. Kisspeptin could
therefore limit fetal invasion both by suppressing placental MMP9
expression as well as inhibiting placental bed angiogenesis via the
suppression of VEGF A expression.
It should however be borne in mind that all the above findings
are a description of the feto-maternal interphase at term. This is an
acknowledged limitation of the study as a description of the
molecular details of this interphase in early pregnancy would
provide more information on feto-maternal dialogue. Nonetheless
attempting such a study in early pregnancy could prove
challenging firstly because true placental bed biopsies comprising
decidua, extravillous trophoblast and myometrium might prove
difficult to attain in early pregnancy and secondly studies of such a
nature (ie involving placental bed sampling) might be limited by
ethical considerations.
In summary our study has examined differential gene expression
in both the fetal and maternal compartments of the feto-maternal
interface. Figure 8 depicts a schematic representation of the
anatomy of the feto-maternal interface (Fig. 8a) as well as the
putative interactions of factors examined in this study at this
interface (Fig. 8b). We have found high fetal expression of Kiss1,
GPR54 as well as MMP9 which are all genes involved in invasion
suggesting that the control of invasion capacity (at least involving
these genes) may predominantly be exercised at the fetal level.
Examination of genes involved in angiogenesis revealed high
expression of PROK1 and PROK1R ligand-receptor pair in the fetus
and high expression of VEGF-A and VEGFR2 ligand-receptor pair
on the maternal side. VEGFR1, which is anti-VEGF, was highly
expressed in the fetus. These findings may be suggestive of
angiogenesis being prokineticin-driven in the placenta while
maternal angiogenesis in the placental bed is mainly mediated
by VEGF-A. Further studies will be required to explore the
potential of this dual angiogenesis hypothesis. The findings could
unveil the possible prophylactic use of VEGFR2 agonists in
women with a predilection for preeclampsia and the potential use
of PROK1 agonists in the treatment of fetuses with growth
restriction. Having defined the differential gene expression profiles
across the feto-maternal interface of healthy pregnancies, further
studies need to compare these profiles with those of pathological
pregnancies.
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